Insmed Incorporated (INSM) SEC Filings & Earnings Calls

CFO departure could create temporary leadership gap; search underway.

“Sara Bonstein, the Company’s Chief Financial Officer, would be separating from the Company, effective October 30, 2026, and the Company has a search underway to identify a successor” · word for word

Dependence on BRINSUPRI launch success and regulatory approvals

“BRINSUPRI is new product; regulatory decisions in Japan and label expansion for ARIKAYCE pending.”

High R&D and SG&A spending growth

“R&D up 19% YoY, SG&A up 60% YoY, though partially offset by contingent consideration fair value change.”

Customer concentration

“Customer A 38 % 28 % Customer B 22 % 28 % Customer C 18 % 9 % Customer D 14 % 5 %” · word for word

Dependence on third-party manufacturers

“The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results.” · word for word

Contingent consideration volatility

“Change in fair value of contingent consideration ( 99,760 ) 59,000 ( 146,721 ) 77,300” · word for word

Clinical trial risk: OLE data may not predict Phase 3 results

“Forward-looking statements note risk that OLE data may not be consistent with Phase 3 PALM-PAH trial.”

Regulatory approval risk for TPIP

“TPIP is investigational; no assurance of FDA approval.”

High Operating Cash Burn

“Net cash used in operating activities was $222.7 million for Q1 2026.” · word for word

Clinical Trial Failure

“The Phase 2b CEDAR study of brensocatib in HS did not meet its primary or secondary efficacy endpoints.” · word for word

Dependence on BRINSUPRI Launch Success

“BRINSUPRI revenue of $207.8M in Q1 2026 represents 68% of total product revenue.”

Commercial execution risk: sustained BRINSUPRI growth depends on market adoption and competition.

“BRINSUPRI global revenue grew 44% in the first quarter of 2026 compared to the fourth quarter of 2025.” · word for word

Regulatory risk: label expansion for ARIKAYCE and international approvals for BRINSUPRI subject to regulatory decisions.

“Insmed plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for ARIKAYCE in all patients with MAC lung disease in the second half of 2026.” · word for word

Clinical trial failure for brensocatib in HS; program discontinuation may impact pipeline value and investor sentiment.

“Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program.” · word for word

Clinical trial failure in CRSsNP

“The study did not meet its primary or secondary efficacy endpoints, and we discontinued our development program for brensocatib in CRSsNP.” · word for word

Net loss continues to widen

“GAAP Net Income (Loss) ($ in thousands) 2025 (1,276,775)” · word for word

Safety profile consistent with known profile; no new safety signals; discontinuation rate 18.3% vs 11.8% in comparator arm.

“The safety profile was consistent with the known safety profile of ARIKAYCE, and no new safety signals were observed. The treatment discontinuation rate was 18.3% in the ARIKAYCE arm and 11.8% in the comparator arm.” · word for word

Regulatory and policy risks for international launches

“Insmed continues to evaluate the potential effect of evolving U.S. policies which will then impact the timing for future potential international commercial launches.” · word for word

Clinical trial failure risk

“There is a high rate of failure inherent in this process, and potential products that appear promising at early stages of development may fail for a number of reasons.” · word for word

Regulatory approval risk for drug-device combination

“As ARIKAYCE is a drug/device combination product, we cannot sell ARIKAYCE without Lamira. Any failure to secure or maintain regulatory approval in each market for Lamira as a delivery system for ARIKAYCE may limit our ability to successfully commercialize ARIKAYCE.” · word for word

Market size overestimation risk

“Our estimates of the size of these potential markets for ARIKAYCE, BRINSUPRI, and our product candidates could prove to be overstated, perhaps materially.” · word for word

Operating loss and cash burn

“We expect to continue to incur consolidated operating losses, including losses at our US and certain international entities, as we plan to fund R&D for ARIKAYCE, TPIP, brensocatib, INS1148, INS1201, INS1202, and our other pipeline programs.” · word for word

Clinical trial risk: ENCORE and CEDAR topline results pending; failure could impact pipeline value.

“Topline data from Phase 3 ENCORE and Phase 2b CEDAR studies anticipated in 2026.”

Clinical trial failure for brensocatib in CRSsNP; pipeline uncertainty.

“Phase 2b study did not meet endpoints; program discontinued.”

Clinical trial failure risk

“We anticipate reporting topline data from the ENCORE trial in the first half of 2026, with the submission of a US supplementary new drug application for ARIKAYCE in all patients with MAC lung disease projected for the second half of 2026.” · word for word

Commercialization risk for new product

“We also expect to continue to incur significant costs related to the commercialization of our marketed products and commercial activities as we launch BRINSUPRI for patients with bronchiectasis.” · word for word

Dependence on successful pipeline execution and regulatory approvals for future growth.

“Multiple Phase 3 studies planned; regulatory submissions pending in EU, UK, Japan”

Cost of product revenues increasing faster than revenue growth, potentially pressuring margins.

“Cost of product revenues $29.4M vs $21.2M prior year, +38.7% vs revenue +52%”